Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Spironolactone  COVID-19 treatment studies for Spironolactone  C19 studies: Spironolactone  Spironolactone   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
 
Spironolactone COVID-19 studies. Recent:
Holt
Mareev
Jeon
Ersoy
Davarpanah
Abbasi
MacFadden.
Submit updates/corrections.
Oct 4
Covid Analysis (Preprint) (meta analysis) Spironolactone for COVID-19: real-time meta analysis of 10 studies
Statistically significant improvements are seen for mortality, progression, and recovery. 9 studies from 9 independent teams in 8 different countries show statistically significant improvements in isolation (7 for the most serious outco..
Jul 6
Cousins et al., medRxiv, doi:10.1101/2022.07.02.22277181 (Preprint) Integrative analysis of viral entry networks and clinical outcomes identifies a protective role for spironolactone in severe COVID-19
69% lower ventilation [p=0.05] and 58% lower ICU admission [p=0.004]. PSM retrospective 64,349 COVID-19 patients in the USA, showing spironolactone associated with lower ICU admission. Authors also present In Vitro research showing dose-dependent inhibition in a human lung epithelial cell line.
Jul 2
Wadhwa et al., medRxiv, doi:10.1101/2022.07.01.22277163 (Preprint) Phase 2 randomised placebo-controlled trial of spironolactone and dexamethasone versus dexamethasone in COVID-19 hospitalised patients in Delhi
72% lower progression [p=0.03], 49% higher hospital discharge [p=0.05], and 18% faster recovery [p=0.06]. RCT 120 hospitalized patients in India, 74 treated with spironolactone and dexamethasone, and 46 with dexamethasone, showing lower progression with treatment. Spironolactone 50mg once daily day 1, 25mg once daily until day 21.
Mar 29
MacFadden et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofac156 Screening Large Population Health Databases for Potential COVID-19 Therapeutics: A Pharmacopeia-Wide Association Study (PWAS) of Commonly Prescribed Medications
7% fewer cases [p=0.008]. Retrospective 26,121 cases and 2,369,020 controls ≥65yo in Canada, showing lower cases with chronic use of spironolactone.
Feb 7
Abbasi et al., Journal of the Endocrine Society, doi:10.1210/jendso/bvac017 A Randomized Trial of Sitagliptin and Spironolactone With Combination Therapy in Hospitalized Adults With COVID-19
55% lower mortality [p=0.1], 34% lower ventilation [p=0.36], 19% lower ICU admission [p=0.67], and 47% improved recovery [p<0.0001]. RCT including 51 spironolactone patients and 87 control patients in Iran, showing improved recovery with spironolactone, sitagliptin, and the combination of both.
Jan 21
Davarpanah et al., medRxiv, doi:10.1101/2022.01.21.22269322 (Preprint) Combination of Spironolactone and Sitagliptin Improves Clinical Outcomes of Outpatients with COVID-19: An Observational Study
78% lower hospitalization [p=0.0008] and 64% faster recovery [p=0.0001]. Prospective study of 206 outpatients in Iran, 103 treated with spironolactone and sitagliptin, showing lower hospitalization and faster recovery with treatment. spironolactone 100mg and sitagliptin 100mg daily.
Oct 13
2021
Ersoy et al., Aydin Sağlik Dergi̇si̇, doi:10.17932/IAU.ASD.2015.007/asd_v07i3002 Assessment Of The Efficacy Of Spironolactone For COVID-19 ARDS Patients
46% lower mortality [p=0.002]. Retrospective 30 COVID-19 ARDS ICU patients and 30 control patients, showing lower mortality with treatment.
Feb 23
2021
Jeon et al., Frontiers in Medicine, doi:10.3389/fmed.2021.629176 Effect of Spironolactone on COVID-19 in Patients With Underlying Liver Cirrhosis: A Nationwide Case-Control Study in South Korea
77% fewer cases [p=0.005]. Retrospective 6,462 liver cirrhosis patients in South Korea, with 67 COVID+ cases, showing significantly lower cases with spironolactone treatment. Death and ICU results per group are not provided.
Dec 3
2020
Mareev et al., Кардиология, doi:10.18087/cardio.2020.11.n1440 Results of Open-Label non-Randomized Comparative Clinical Trial: “BromhexIne and Spironolactone for CoronаvirUs Infection requiring hospiTalization (BISCUIT)
11% improved recovery [p=0.47], 39% higher hospital discharge [p=0.02], 8% shorter hospitalization [p=0.35], and 87% improved viral clearance [p=0.08]. Prospective 103 PCR+ patients in Russia, 33 treated with bromexhine+spironolactone, showing lower PCR+ at day 10 or hospitalization >10 days with treatment. Bromhexine 8mg 4 times daily, spironolactone 25-50 mg/day for 10 days.
Oct 6
2020
Cadegiani et al., medRxiv, doi:10.1101/2020.10.05.20206870 (Preprint) An open-label prospective observational study of antiandrogen and non-antiandrogen early pharmacological approaches in females with mild-to-moderate COVID-19. The Pre-AndroCoV Female Trial
77% faster recovery [p=0.006] and 38% faster viral clearance [p=0.02]. Prospective study of 270 female COVID-19 patients in Brazil, 75 with hyperandrogenism, of which 8 were on spironolactone. Results suggest that HA patients may be at increased risk, and that spironolactone use may reduce the risk compared ..
May 7
2020
Holt et al., Journal of Hypertension, doi:10.1097/hjh.0000000000002515 Influence of inhibitors of the renin–angiotensin system on risk of acute respiratory distress syndrome in Danish hospitalized COVID-19 patients
129% higher combined mortality/ICU admission [p=0.0007]. Retrospective 689 hospitalized COVID-19 patients in Denmark, showing higher risk of ICU/death with spironolactone use in unadjusted results subject to confounding by indication.
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit